Switching from risperidone long-acting injectable to paliperidone long-acting injectable or oral antipsychotics: Analysis of a Medicaid claims database

International Clinical Psychopharmacology

Volumn 30, Issue 3, 2015, Pages 151-157

  Voss, Erica A ^a   Ryan, Patrick B ^a   Stang, Paul E ^a   Hough, David ^a   Alphs, Larry ^a  

^a JANSSEN RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Oral antipsychotic; Paliperidone palmitate; Risperidone long acting injectable; Switching

Indexed keywords

NEUROLEPTIC AGENT; PALIPERIDONE; RISPERIDONE; DELAYED RELEASE FORMULATION;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; COHORT ANALYSIS; DATA BASE; DRUG SUBSTITUTION; FEMALE; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; MEDICAID; MIDDLE AGED; NEWBORN; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROPENSITY SCORE; PSYCHOPHARMACOTHERAPY; RELAPSE; RETROSPECTIVE STUDY; SCHIZOPHRENIA; VERY ELDERLY; ADMINISTRATION AND DOSAGE; DELAYED RELEASE FORMULATION; DRUG ADMINISTRATION; FACTUAL DATABASE; INSURANCE; ORAL DRUG ADMINISTRATION; PROCEDURES; PROSPECTIVE STUDY; TRENDS; UNITED STATES;

ADMINISTRATION, ORAL; ADULT; ANTIPSYCHOTIC AGENTS; COHORT STUDIES; DATABASES, FACTUAL; DELAYED-ACTION PREPARATIONS; DRUG ADMINISTRATION SCHEDULE; DRUG SUBSTITUTION; FEMALE; HUMANS; INSURANCE CLAIM REVIEW; MALE; MEDICAID; MIDDLE AGED; PALIPERIDONE PALMITATE; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; RISPERIDONE; SCHIZOPHRENIA; UNITED STATES;

EID: 84927125015     PISSN: 02681315     EISSN: 14735857     Source Type: Journal    
DOI: 10.1097/YIC.0000000000000068     Document Type: Article

References (25)

1. American Psychiatric Association (1997). Practice guideline for the treatment of patients with schizophrenia. Am J Psychiatry 154:1-63.
2. Austin PC (2011). Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies. Pharm Stat 10:150-161.
3. Defalco FJ, Ryan PB, Soledad Cepeda M (2013). Applying standardized drug terminologies to observational healthcare databases: a case study on opioid exposure. Health Serv Outcomes Res Methodol 13:58-67.
4. Faries DE, Ascher-Svanum H, Nyhuis AW, Kinon BJ (2009). Clinical and economic ramifications of switching antipsychotics in the treatment of schizophrenia. BMC Psychiatry 9:54.
5. Fusar-Poli P, Kempton MJ, Rosenheck RA (2013). Efficacy and safety of secondgeneration long-acting injections in schizophrenia: a meta-analysis of randomized-controlled trials. Int Clin Psychopharmacol 28:57-66.
6. Genkin A, Lewis DD, Madigan D (2007). Large-scale Bayesian logistic regression for text categorization. Technometrics 49:291-304.
7. Kane JM, Detke HC, Naber D, Sethuraman G, Lin DY, Bergstrom RF, McDonnell D (2010). Olanzapine long-acting injection: a 24-week, randomized, double-blind trial of maintenance treatment in patients with schizophrenia. Am J Psychiatry 167:181-189.
8. Kirson NY, Weiden PJ, Yermakov S, Huang W, Samuelson T, Offord SJ, et al. (2013). Efficacy and effectiveness of depot versus oral antipsychotics in schizophrenia: synthesizing results across different research designs. J Clin Psychiatry 74:568-575.
9. Macfadden W, Ma YW, Thomas Haskins J, Bossie CA, Alphs L (2010). A prospective study comparing the long-term effectiveness of injectable risperidone long-acting therapy and oral aripiprazole in patients with schizophrenia. Psychiatry (Edgmont) 7 :23-31.
10. Nicholl D, Akhras KS, Diels J, Schadrack J (2010). Burden of schizophrenia in recently diagnosed patients: healthcare utilisation and cost perspective. Curr Med Res Opin 26:943-955.
11. Nyhuis AW, Faries DE, Ascher-Svanum H, Stauffer VL, Kinon BJ (2010). Predictors of switching antipsychotic medications in the treatment of schizophrenia. BMC Psychiatry 10:75.
12. Observational Medical Outcomes Partnership (OMOP) (2014). Vocabularies. Version 4. Observational Medical Outcomes Partnership. Available at: http://omop.org/Vocabularies. [Accessed 16 September 2014].
13. Olivares JM, Rodriguez-Martinez A, Burón JA, Alonso-Escolano D, Rodriguez-Morales A, e-STAR Study Group (2008). Cost-effectiveness analysis of switching antipsychotic medication to long-acting injectable risperidone in patients with schizophrenia : a 12- and 24-month follow-up from the e-STAR database in Spain. Appl Health Econ Health Policy 6:41-53.
14. Olivares JM, Peuskens J, Pecenak J, Resseler S, Jacobs A, Akhras KS, e-STAR Study Group (2009a). Clinical and resource-use outcomes of risperidone long-acting injection in recent and long-term diagnosed schizophrenia patients: results from a multinational electronic registry. Curr Med Res Opin 25:2197-2206.
15. Olivares JM, Rodriguez-Morales A, Diels J, Povey M, Jacobs A, Zhao Z, et al. (2009b). Long-term outcomes in patients with schizophrenia treated with risperidone long-acting injection or oral antipsychotics in Spain: results from the electronic Schizophrenia Treatment Adherence Registry (e-STAR). Eur Psychiatry 24:287-296.
16. Overhage JM, Ryan PB, Reich CG, Hartzema AG, Stang PE (2012). Validation of a common data model for active safety surveillance research. J Am Med Inform Assoc 19:54-60.
17. Reich C, Ryan PB, Stang PE, Rocca M (2012). Evaluation of alternative standardized terminologies for medical conditions within a network of observational healthcare databases. J Biomed Inform 45:689-696.
18. Rosenbaum PR, Rubin DB (1983). The central role of the propensity score in observational studies for causal effects. Biometrika 70:41-55.
19. Rosenheck RA, Krystal JH, Lew R, Barnett PG, Fiore L, Valley D, et al. (2011a). Long-acting risperidone and oral antipsychotics in unstable schizophrenia. N Engl J Med 364:842-851.
20. Rosenheck RA, Krystal JH, Lew R, Barnett PG, Thwin SS, Fiore L, et al. (2011b). Challenges in the design and conduct of controlled clinical effectiveness trials in schizophrenia. Clin Trials 8:196-204.
21. Ryan PB (2010). Establishing a drug era persistence window for active surveillance. Observational Medical Outcomes Partnership. Available at: http://omop.org/sites/default/files/OMOP-Establishing%20a%20Drug%20Era%20Persistence%20Window%20for%20Active%20Surveillance-Jan%202010.pdf. [Accessed 16 September 2014.].
22. Schooler NR (2003). Relapse and rehospitalization: comparing oral and depot antipsychotics. J Clin Psychiatry Suppl 16:14-17.
23. Weiden PJ (2006). Switching in the era of atypical antipsychotics. An updated review. Postgrad Med Spec No:27-44.
24. Weiden PJ, Olfson M (1995). Cost of relapse in schizophrenia. Schizophr Bull 21:419-429.
25. Wu EQ, Birnbaum HG, Shi L, Ball DE, Kessler RC, Moulis M, Aggarwal J (2005). The economic burden of schizophrenia in the United States in 2002. J Clin Psychiatry 66:1122-1129.